Publication Name	World Journal of Clinical Oncology
Manuscript ID	119615
Country	China

Category	Oncology
Manuscript Type	Case Report
Article Title	Anlotinib plus albumin-bound paclitaxel induction-maintenance for sorafenib-refractory radioiodine-refractory differentiated thyroid cancer: A case report and review of literature
Manuscript Source	Unsolicited Manuscript
All Author List	Chun-Yan Zhou, Xin-Yi Ren, Huan-Huan Li, Xiao-Mei Pan, Xin Lan and Dong Duan
Funding Agency and Grant Number	Funding Agency Grant Number Natural Science Foundation of Chongqing, China CSTB2023NSCQ-MSX0678
Corresponding Author	Dong Duan, Department of Nuclear Medicine, Chongqing General Hospital, 118 Xingguang Avenue, Liangjiang New Area, Chongqing 400700, China. duandong26@163.com
Key Words	Radioiodine-refractory differentiated thyroid cancer; Anlotinib; Albumin-bound paclitaxel; Combination therapy; Maintenance therapy; Case report
Core Tip	Effective salvage treatments for radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) following sorafenib failure remain severely limited. This case report presents an innovative combination and maintenance strategy. By employing anlotinib plus albumin-bound paclitaxel as induction therapy to potentially promote vascular normalization and enhance cytotoxic drug delivery, followed by anlotinib maintenance, a patient with metastatic RAIR-DTC achieved a confirmed partial response. With manageable toxicity and progression-free survival exceeding 38 months, this case suggests that the anlotinib-based regimen may provide durable disease control and warrants further prospective evaluation in patients who have exhausted first-line multikinase inhibitors.
Citation	Zhou CY, Ren XY, Li HH, Pan XM, Lan X, Duan D. Anlotinib plus albumin-bound paclitaxel induction-maintenance for sorafenib-refractory radioiodine-refractory differentiated thyroid cancer: A case report and review of literature. World J Clin Oncol 2026; In press

Received	2026-02-02 02:22
Peer-Review Started	2026-02-02 02:23
First Decision by Editorial Office Director	2026-02-12 08:21
Return for Revision	2026-02-12 08:21
Revised	2026-03-06 15:30
Publication Fee Transferred	2026-03-08 11:16
Second Decision by Editor	2026-04-01 02:44
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-04-01 06:31
Articles in Press	2026-04-01 06:31
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com